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Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that include obesity, impaired glucose tolerance
or diabetes, hyperinsulinemia, hypertension, and dyslipidemia. Recently, more attention has been reserved to the
correlation between periodontitis and systemic health. MetS is characterized by oxidative stress, a condition in
which the equilibrium between the production and the inactivation of reactive oxygen species (ROS) becomes
disrupted. ROS have an essential role in a variety of physiological systems, but under a condition of oxidative stress,
they contribute to cellular dysfunction and damage. Oxidative stress may act as a common link to explain the
relationship between each component of MetS and periodontitis. All those conditions show increased serum levels
of products derived from oxidative damage, promoting a proinflammatory state. Moreover, adipocytokines,
produced by the fat cells of fat tissue, might modulate the balance between oxidant and antioxidant activities.
An increased caloric intake involves a higher metabolic activity, which results in an increased production of ROS,
inducing insulin resistance. At the same time, obese patients require more insulin to maintain blood glucose
homeostasis – a state known as hyperinsulinemia, a condition that can evolve into type 2 diabetes. Oxidation
products can increase neutrophil adhesion and chemotaxis, thus favoring oxidative damage. Hyperglycemia and an
oxidizing state promote the genesis of advanced glycation end-products, which could also be implicated in the
degeneration and damage of periodontal tissue. Thus, MetS, the whole of interconnected factors, presents systemic
and local manifestations, such as cardiovascular disease and periodontitis, related by a common factor known as
oxidative stress.
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This review inquires into and tries to clarify the relation-
ship between metabolic syndrome and periodontitis.
Periodontitis is a family of diseases that affect dental
supporting tissues, caused by infections sustained by
periodontal pathogens such as Porphyromonas gingivalis,
Prevotella intermedia, Tannarella forsythia, and Aggrega-
tibacter actinomycetmcomintans, which lead to soft and
hard tissue destruction, dental mobility, and the loss of
dental elements [1].
Susceptibility to these diseases is highly variable and
depends on host responses to periodontal pathogens.* Correspondence: simtecc@unich.it
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reproduction in any medium, provided the orAlthough bacteria cause plaque-induced inflammatory
periodontal disease, the progression and clinical charac-
teristics of these diseases are influenced by both acquired
and genetic factors that can modify susceptibility to
infection [2].
Periodontitis in the United States has a prevalence of
30% to 50% of the population, but only about 10% have
severe forms. It tends to be more common in economic-
ally disadvantaged populations or regions. Its occurrence
decreases with a higher standard of living. Individuals of
Israeli, Yemenite, North-African, South Asian, or Medi-
terranean origin have a higher prevalence of periodontal
disease than individuals from European areas [3].
Periodontitis must be distinguished from gingivitis
(properly, inflammation of the gum tissue), which is a
term used to describe a non-destructive periodontal dis-
ease [4].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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response to bacterial biofilms adhering to tooth surfaces.
Epidemiologically, gingivitis is the most common form
of periodontal disease. From a prognostic point of view,
in the absence of treatment, gingivitis may progress to
periodontitis, which is a destructive form of periodontal
disease [4], but in some sites or individuals, gingivitis
never progresses to periodontitis [5].
Data indicate that periodontitis is always preceded by gin-
givitis [6], while gingivitis can be prevented through regular
oral hygiene that includes daily brushing and flossing [7,8].
Periodontitis depends on host responses to periodontal
pathogens.
The initial increased presence of neutrophils at the site
is followed by the release of cytokines by neutrophils
and macrophages; the chemical mediators released in-
clude tumor necrosis factor alpha (TNF-α), interleukin-1
(IL-1), and prostaglandins.
The inflammatory process includes the stimulation of
fibroblasts by IL-1 and the secretion of matrix metallo-
proteinases (MMP), of which collagenase is the most
prominent, by polymorphonuclear neutrophils. MMPs
are responsible for increased collagen breakdown, and
TNF-α is primarily responsible for increased osteoclast
activity resulting in bone resorption.
T-lymphocytes secrete receptor activator of nuclear
factor kappa-B ligand (RANKL), which is involved in
osteoclast activity and, therefore, bone resorption [9].
Periodontitis has also been associated with elevations
in circulating levels of IL-6 and C-reactive protein
(CRP). IL-6 is an important proinflammatory cytokine
involved in the regulation of host response to tissue
injury and infection. It is produced by a variety of cells,
such as monocytes, fibroblasts, osteoblasts, and vascular
endothelial cells, in response to inflammatory challenges.
Moreover, it is widely accepted that IL-6 induces CRP
production.
In addition, a significant overexpression of IL-21,
IL-1β, IL-17, and IL-23p19 has been detected in tissues
affected by periodontal disease compared with healthy
gingival tissues. In particular, IL-21 is overexpressed in
chronic periodontitis gingival tissues and is correlated
with the clinical parameters of periodontal destruction
and with proinflammatory cytokines [10].
A negative modulatory role of IL-4 and IL-13 in osteo-
tropic cytokine production could be a mechanism that
plays an important inhibitory role in inflammation-
induced periodontitis. In facts the activation of STAT6
by IL-4 and IL-13, through type 2 IL-4 receptors, seems
to inhibit the production of IL-11 and leukemia inhibi-
tory factor stimulated by IL-1β and TNF-α in human
gingival fibroblasts [11].
In addition, IL-10 and tumor growth factor-β1 (TGF-β1)
are down-regulated in periodontal lesions. Generalizedaggressive periodontitis subjects are characterized by a
higher IL-1β/IL-10 ratio than are periodontally healthy sub-
jects, suggesting an imbalance between pro- and anti-
inflammatory cytokines in generalized aggressive periodon-
titis. IL-10 is also associated with periodontal health and
seems to be a regulator of inflammation and alveolar
bone loss in periodontal diseases. It might be involved in
controlling the inflammatory process at periodontally
healthy sites [11].
Metabolic syndrome
Metabolic syndrome (MetS) is characterized by multiple
disorders. Oxidative stress seems to have a great role in
the ethiopathogenesis of MetS and is the common factor
useful to explain the interconnection of all the compo-
nents of MetS.
In this review we analyze singularly the overlapping
factors of each component and the common ways of
ethiopathogenesis Figure 1.
MetS is a pathology largely diffused in western coun-
tries. Its diagnostic criteria have only recently been
better defined, even though they are still ambiguous,
because these diseases, including obesity, hyperglycemia,
hyperinsulinemia, and dyslipidemia, are all considered
serious risk factors for heart diseases [12,13]. As MetS is
characterized by numerous factors, it is very difficult to
establish a correct diagnosis and an adequate therapy.
MetS was initially defined as Syndrome X by Reaven
[12] and then as the “deadly quartet,” referring to the
synergy of its components, such as hyperinsulinemia,
hypertension, hypertriglyceridemia, and visceral obesity.
Subsequently, it was defined as insulin-resistance syn-
drome, since authors believed that insulin resistance was
the dominant factor predisposing the occurrence of
other symptoms.
Besides the risk factors already mentioned, other pecu-
liarities that seem to be associated with MetS include
hepatic steatosis, inflamed adipose tissue, enhanced clot-
ting factor activity, endothelial dysfunction, inflamma-
tion, and obviously oxidative stress [14].
Numerous definitions have been proposed for MetS,
but the criteria proposed by the National Cholesterol
Education Program (NCEP) Adult Treatment Panel III
are actually the most used [15]. The American Heart
Association describes MetS as a syndrome characterized
by a group of metabolic risk factors in an individual
[16]. These factors include the following:
 Abdominal obesity, i.e., excessive fat tissue in and
around the abdomen;
 Atherogenic dyslipidemia, i.e., blood fat disorders, high
triglycerides, low high-density lipoprotein cholesterol
(HDL-C), and high low-protein lipoprotein cholesterol
(LDL-C) that foster plaque buildup in the artery walls;
Figure 1 Flow chart that indicates the pathophysiological mechanism underlying the onset of Mets.
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 Insulin resistance or glucose intolerance, i.e., the
body cannot properly use insulin or blood sugar;
 Prothrombotic state, e.g., high fibrinogen or
plasminogen activator inhibitor-1 in the blood; and
 Proinflammatory state, e.g., elevated CRP in the
blood.
The American Heart Association and the National
Heart, Lung, and Blood Institute recommend that MetS
be identified as the presence of three or more of the fol-
lowing components:
 Elevated waist circumference:
 Men – equal to or greater than 40 inches (102 cm);
 Women – equal to or greater than 35 inches
(88 cm);
 Elevated triglycerides: equal to or greater than
150 mg/dL;
 Reduced HDL (“good”) cholesterol:
 Men – less than 40 mg/dL;
 Women – less than 50 mg/dL;
 Elevated blood pressure: equal to or greater than
130/85 mm Hg;
 Elevated fasting glucose: equal to or greater than
100 mg/dL.
However, some authors do not find as clinically
useful MetS diagnosis as a defined entity. They con-
sider definition criteria and clinical and laboratoryparameters to be ambiguous and incomplete, and the
cardiovascular risk factors associated with MetS
the same as pathologies considered separately
[17]. Moreover, they argue that total therapy does not
differ from that for each single disease and that the
hypothesis of insulin resistance as a common cause is
uncertain [18].
People with MetS are at increased risk of coronary
heart disease or other diseases related to plaque
buildup in the artery walls, such as stroke and periph-
eral vascular disease and type 2 diabetes. The prepon-
derant, fundamental risk factors for this syndrome
appear to be obesity and insulin resistance, but other
conditions associated with the syndrome include phys-
ical inactivity, aging, hormonal imbalance, and genetic
predisposition as seen in the handicapped and senior
citizens.
The necessity of organizing the exact diagnosis of
MetS arises from the need to determine patients at
extreme risk of developing cardiovascular disease
(CVD) and to establish an appropriate therapy and
prevention [19]. The first goal of the clinical manage-
ment of MetS is to reduce the major risks for CVD
and type 2 diabetes by stopping smoking, stabilizing
LDL and blood pressure parameters, maintaining glu-
cose levels at the recommended values, reducing body
weight (body mass index less than 25 kg/m2) through
an adapted diet, and doing moderate-intensity physical
activity for at least 30 minutes on most days of the
week.
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As previously shown, the role of oxidative stress in the
ethiopathogenesis of MetS and its characteristic signs is
widely supported [20].
Reactive oxygen species (ROS) are physiologically pro-
duced by the cellular metabolism. They are highly reactive
species, able to exist independently, and are characterized
by the presence of unpaired electrons that allow inter-
action with a great number of biomolecules, causing their
oxidation [17,21]. Exogenous sources of ROS are smok-
ing, ultraviolet light, heat, ultrasound, ozone, radiation,
exhaust fumes, infection, excessive exercise, trauma, and
drugs, whereas endogenous sources include products of
metabolic pathways and products of immune and con-
nective tissue cells [22,23]. Antioxidants are substances
that can inhibit the action of oxidant species [21]. There
is a physiological fine balance between oxidant activities
and antioxidant defenses, but when this equilibrium is
disrupted to the advantage of ROS, or to increased ROS
activity or to want of antioxidant defenses, the result is
oxidative stress [22]. In this condition ROS operate by
creating an adequate environment for phagocytic vacuole
and enzymatic digestion, and by mediating cellular signal-
ing. An amplified activity of ROS implies a large spectrum
of molecular and cellular damage, such as lipoxidation.
This results in covalent binding with proteins, which
alters their structure and function [22]. Some oxidized
proteins are difficult to remove by cells and tend to accu-
mulate with aging and in the presence of chronic diseases
such as diabetes mellitus.
Several studies have demonstrated a real correlation
between oxidative stress and MetS. In fact, in patients
suffering from MetS, systemic oxidative stress seems to
be more elevated than in healthy controls, and antioxi-
dant defense seems to be decreased, as demonstrated by
the diminished rate of Vit C, α-tochopherol, and super-
oxide dismutase activity in serum, and by increased
lipoxidation [24]. Moreover, obesity is firmly related to
oxidative stress–mediated endothelial damage [25]. An
increased caloric excess not balanced by an elevated
energy expense leads to an increase in the metabolism of
Krébs cycle, generating a ROS excess [26]. Some HDL-C
subfractions present antioxidant activity that is dimin-
ished in people suffering from MetS, and this reduction
is correlated with systemic oxidative stress and insulin
resistance. Furthermore, obese adults with MetS have an
increased plasmatic rate of oxidized LDL-C compared
with obese patients without this syndrome [27]. In
addition, individuals suffering from MetS present an
increased presence of serum lipid peroxide compared
with healthy controls [28].
Insulin resistance is a condition in which the normal
amount of insulin is insufficient to obtain an adequate
response from muscular and adipose tissues and fromhepatic cells, and this leads to a severe hyperglycemia
with deleterious systemic effects [29-32], such as lower
intracellular antioxidant defenses [31,32].
A great number of studies have focused on molecules
that can reduce oxidative stress. Recently, for example,
some studies have proposed tetracycline as useful in
combating oxidative stress in periodontitis and meta-
bolic disorders. In fact, in addition to its antimicrobial
effect, it shows antioxidant, anti-inflammatory, proana-
bolic, immunomodulatory, angiogenetic, and antiapopto-
tic effects [33,34]. Decreased yields of oxidative stress
were also obtained in the presence of minocycline, which
demonstrates its potential role as an adjunctive thera-
peutic agent in an environment of oxidative stress, such
as in periodontal disease and coexisting cardiometabolic
pathologies [35]. Then, the beneficial systemic effect of
the antioxidant tempol on apical periodontitis in both
control and pathological rats with doxorubicin-elicited
cardiomyopathy has also been evidenced [36]. In addition,
a recent study focused on the antioxidant, anti-human
immunodeficiency virus, anticarcinogenic, and anti-
inflammatory properties of Gomisins G and J extracted
from Schisandra chinensis, as it seems to inhibit Porphyr-
omonas gingivalis [37]. Furthermore, the proanthocyani-
dins (PAC), the most abundant flavonoids extracted
from red cranberry fruits, have been reported to pos-
sess antimicrobial, antiadhesion, antioxidant, and anti-
inflammatory properties. The PACs have variable
pharmacological and nutraceutical benefits, including
improvement of ischemic CVD, prevention of athero-
sclerosis, and antiarthritic, anticancer, and antimicrobial
activities. A recent in vitro study has shown that cran-
berry PACs may be also potential therapeutic agents for
the prevention and management of periodontitis [38].
Thymoquinone has also demonstrated a variety of
pharmacologic properties, including antihistaminic, antibac-
terial, antihypertensive, hypoglycemic, anti-inflammatory,
and antioxidative activities. Through its anti-inflammatory
and antioxidant properties, thymoquinone seems to play an
important role in preventing periodontal diseases [39].
Aso, S-nitrosoglutathione is a nitric oxide donor that
seems to exert antioxidant, anti-inflammatory, and
microbicidal actions, and has been demonstrated as a
potential drug for the topical treatment of periodontitis
[40]. Finally, because of its anti-inflammatory effects, a
novel α-iso-cubebenol isolated from the dried fruit of S.
chinensis is considered a novel therapeutic agent to
ameliorate periodontitis [41].Hyperglycemia and periodontal diseases
Diabetes, a pathology that is extremely widespread,
involves an adulterated homeostasis in the glucose
metabolism. Two types of diabetes exist: type 1 diabetes
Marchetti et al. Nutrition & Metabolism 2012, 9:88 Page 5 of 13
http://www.nutritionandmetabolism.com/content/9/1/88and type 2 diabetes (T2D). Either typology of diabetes, if
not controlled, is a risk factor for periodontitis.
The first type affects young people and sets in from
childhood. The pathological mechanism is that β cells of
Langerhans are unable to produce insulin. Consequently,
glucose tends to accumulate in the tissues and the blood.
The pathology develops in middle age.
T2D is the most common type and consists in an
adulterated insulin cellular response. The onset of T2D
is associated with the recruitment of proinflammatory
cytokines that are involved in the onset of the disease
and related complications such as dyslipidemia and ath-
erosclerosis, contributing to the onset of microvascular
and macrovascular complications [42,43].
Furthermore, patients with periodontitis show a higher
risk of ketoacidosis, retinopathy, and neuropathy than do
diabetic patients without periodontal disease. In addition,
diabetic patients with neurological complications have
severe gingivitis compared with diabetic individuals with-
out this complication. Many studies demonstrate a bio-
logical relation between diabetes and periodontitis, as
tested relations exist between glycated hemoglobin, a dia-
betic marker, and periodontal parameters, and between
plasmatic lipid peroxide, an index of oxidative stress, and
periodontal markers [44,45].
Regarding the mechanism involved in this association,
it seems that prolonged hyperglycemia associated with
diabetes causes the formation of advanced glycation
end-products (AGE). AGEs are physiologically produced
by the organism, but in conditions of hyperglycemia or
augmented oxidative stress their presence is largely aug-
mented. Exogenous sources of AGE are smoking and
browned foods [46]. AGEs result from reversible glyca-
tion reactions, that is, the addition of sugars on the poly-
peptide chain of proteins, lipids, or nucleic acids.
Whether an enzyme attends or not in the glycation reac-
tions, we can have an enzymatic or nonenzymatic glyca-
tion [46]. Furthermore, more resistant proteins such as
interstitial or vassal collagen can undergo a nonenzy-
matic glycation. Several cells, such as endothelial, mus-
cular, and immune cells, possess specific AGE receptors,
called RAGE. In fact, a confirmation of AGE activity
against periodontal tissue is proved by an elevated pres-
ence of RAGE in the periodontal compartment [47].
AGEs have deleterious effects for the organism and,
being resistant to proteolytic digestion, are difficult to
eliminate and tend to accumulate, expressing their
harmful effect. AGE-degradation products are chiefly
expelled through urine [48].
AGEs are substances able to promote cytokine pro-
duction by macrophages such as TNF-α and IL-6, and to
stimulate hepatic secretion of acute-phase proteins such
as CRP, fibrinogen, plasminogen activator/inhibitor, and
serum amyloid A, also correlated with oral infection andcardiovascular diseases, especially in patients suffering
from periodontal diseases [46,48]. AGEs also promote
monocyte migration and increase endothelial permeability,
fibroblasts, and muscular cell activity [46]. In addition,
AGEs can bind collagen, which if modified alters base-
ment membrane structure. This gives to an inhibition of
oxygen diffusion and tissular oxygenation, diminished
waste removal, altered immune mediators, and migration
that causes an adulterate inflammatory response, which
results in inadequate tissue recovery [42].
AGEs also lead to the rapid expansion of energy in the
respiratory polymorphonuclear neutrophils (PMN), and
this causes increased damage to periodontal tissues
[42,49] and some changes in bone metabolism, especially
on repair, also reducing the production of the extracel-
lular matrix [50].
The course of the periodontal illness may be due to
basic neutrophilic activity that results in an exaggerated
immune response and an uncontrolled ROS production.
These cause local and peripheral oxidative damage, both
directly, through oxidative injury, and indirectly, by
means of redox-sensitive gene transcription factors.
Nuclear factor kappa B and activating protein 1 are acti-
vated, triggering an inflammatory mediator cascade and
quick cellular aging [51].
Diabetic patients with severe periodontitis have demon-
strated a reduced chemotaxis of PMN compared with
healthy subjects, or patients with less aggressive peri-
odontitis, and an altered control of apoptosis, which is
followed by an accumulation of PMNs in the periodontal
tissues and therefore of MMPs and ROS [50]. The lack of
glycemic control has also been associated with alterations
in the oral mucosa barrier [52]. The presence of diabetes
seems to increase inflammation in the periodontium, so
much so that in the gingival crevicular fluid there are
increased levels of PGE2 and IL1-β compared with paro-
dontopatic normoglycemic patients. Moreover, the pres-
ence of diabetes mellitus prolongs the inflammatory
response to P. gingivalis, causing an increase in the pro-
duction of TNF-α [50].
In synthesis, diabetes appears correlated to the onset of
periodontal diseases, both through changes in the host
immune response and through anomalies in the collagen
metabolism. Recently, different molecules have been
investigated for the treatment of diabetes.
Decursin (De), an active component of Angelica gigas,
known to exert anticancer and neuroprotective effects,
was recently studied for its antiobesity and antidiabetic
potential. De treatment resulted in the inhibition of
adipocyte differentiation and expression of fatty acid
synthase. Administration of De along with a high-fat
diet (HFD) significantly reduced the secretion of HFD-
induced adipocytokines such as leptin, resistin, and
IL-6 [53].
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temic inflammatory state. A recent study suggested a
concrete relationship between severe periodontitis and
systemic oxidative stress with a reduction in antioxidant
systemic defenses. Moreover, it seems that after a peri-
odontal treatment, a transitory inflammatory acute
response occurs with a concomitant increase of sys-
temic oxidative markers [54]. In periodontal diabetic
individuals suffering from T2D, there is an augmented
rate of oxidative systemic markers and a diminished
plasma small-molecule antioxidant capacity [54]. These
patients also show reduced β-cell activity. Therefore, it
seems that periodontitis enlarges oxidative stress–
mediated dysfunction in β-cells of Langerhans [55].
Even in periodontitis, the mediated response of the
host, in the presence of bacterial infections, results in
an increased release of systemic inflammatory media-
tors. The toll-like receptors (TLR), the receptors for
the Ig superfamily (TLR4), and RAGE are implicated in
the intensification of the systemic immune response
during chronic diseases, such as diabetes and periodon-
tal disease [47]. Fibroblasts, macrophages, and epithe-
lial cells present in the periodontium possess both
RAGE and TLR4 [47]. It seems that hyperglycemia can
promote the expression of these receptors in the peri-
odontal district and increase the response to their
ligands, favoring the accumulation of these ligands [47].
Several studies have shown how chemical and mechan-
ical periodontal treatment may improve glycemic and
lipidic control in time [56-60]. It seems that periodon-
tal therapy leads to a reduction in the glycated
hemoglobin (HbA1c) plasma rate and to a better lipidic
profile [59,60].
Atheroma and periodontitis
Periodontitis also contributes to atherosclerosis and
CVD [61].
Periodontal pathogens draw lymphocytes in an attempt
to stem infection through phagocytosis and killing, caus-
ing augmented production of ROS, which ends in a situ-
ation of oxidative stress. The presence of ROS promotes
chemotaxis and recruits inflammatory mediators from
the liver, causing periodontal destruction and favoring
the making of endothelial atheromas.
Periodontal pathogens are also able to invade the
endothelium and atheromas; in fact, oral infection, being
a source of bacteria, is associated with CVD [62].
There are several theories that attempt to explain the
correlation between periodontitis and CVD [63].
One theory is the bacteriological theory, according
to which oral pathogens, such as P. gingivalis, invade
the systemic circulation and by means of the virulence
factors, such as fimbriae, are able to invade the ather-
omatous plaques. These bacteria can activate endothelialcells through TLR4 and induce apoptosis in these cells,
disrupting the mechanisms of cell adhesion.
The inflammatory theory holds that in the course of
periodontitis, gingival cells produce inflammatory media-
tors such as TNF-α, IL-6, PGE-2, and MMPs that locally
promote tissue destruction and, once in the circulation,
stimulate endothelial cells to produce other mediators
such as monocyte chemotactic protein (MCP-1), macro-
phage colony stimulating factor (MCSF), intercellular
adhesion molecule (I-CAM), vascular cell adhesion
molecule (V-CAM), P-selectin, and E-selectin. These
cytokines accelerate the formation of atheroma.
The third theory is the autoimmune theory, according
to which antibodies against bacterial antigens may also
react against endothelial protein, causing their destruc-
tion and therefore the arterial lesion [63].
Systemic and local chronic inflammatory states, such
as periodontitis and MetS, are characterized by an ele-
vated presence of acute-phase proteins such as CRP and
fibrinogen, which represent a decisive contribution to
the insurgence of atherosclerosis and CVD [63]. Vice-
versa, the reduction of periodontal inflammation
through plaque control, systemic antibiotics, scaling, and
root planning seems to decrease CRP levels in patients
suffering from MetS, reducing the risk of CVD [63].
Obesity and periodontal damage
The clear relationship between obesity and periodontitis
is well documented [64-92]. Overweight is a clear risk
factor for the onset of T2D and CVD, as well as for
respiratory and pressure disorders, osteoarthritis, repro-
ductive abnormality, hepatitis, and some types of cancer
[64]. Adipocytes of fat tissue show the ability to secrete
adipocytokines, which seem to be very important in con-
trolling appetite and body weight. One of these cytokines
is leptin, which shows a protective role against obesity
[17]. In fact, a condition of clear obesity can be also
defined as a situation of leptin resistance with a conse-
quent leptinemia [65].
Adipocytes can secrete other cytokines such as adipo-
nectin and resistin. Serum adiponectin remains constant
in normal condition but decreases in the presence of
diabetes, obesity, insulin resistance, and CVD [66].
Resistin shows a great proinflammatory role, and from
studies conducted on mice it seems associated with
insulin resistance [17,22].
However, many researches affirm that the most
important mediator related with obesity and insulin
resistance is TNF-α, expressed plentifully in adipose tis-
sue, in obese individuals with severe insulin resistance,
and in neoplastic patients [67,68]. Both TNF-α and Il-6,
secreted by adipose cells, seem to trouble intracellular
signaling, cause insulin resistance, and stimulate hepatic
production of phase acute-phase proteins such as CRP
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sion of TNF-α or LPS, a TNF-α inductor, can cause a
severe insulin resistance; by contrast, mice missing
TNF-α or its receptor-codifying gene and submitted to
a fatty diet appeared protected against insulin resistance
compared with controls in the same condition having
genes [70]. It seems that when insulin binds its tissular
receptor, a receptor tyrosine residue on the cytoplasmatic
portion is autophosphorylated. The tyrosine residue of the
cytoplasmatic insulin-receptor substrate (IRS-1) binding
insulin receptor is phosphorylated and causes an intracel-
lular signaling, which leads to the membrane recruitment
of intracellular transporter of glucose, GLUT-4, to trap
glucose molecules. TNF-α seems to be able to phosphoryl-
ate a serine residue on IRS-1 and, subsequently, to inhibit
phosphorylation of either the insulin receptor or IRS-1.
Phosphorylation on IRS-1 can also prevent IRS-1 Tyr
phosphorylation on adipocytes [72].
Other authors have supposed that TNF-α can interact
with RNA transcription codifying for IRS-1 and GLUT 4,
compromising their stability. It could also prevent Tyr
phosphorylation of the insulin receptor, inducing hydro-
gen peroxide formation [22,72].
Regarding the relationship between periodontitis and
obesity, recent studies have demonstrated how normal-
weight persons who participate in sports and physical
activity show a decreased incidence of periodontal dis-
ease [73-76]. Recent studies have also demonstrated how
individuals with normal weight showed a lower preva-
lence of periodontitis, decreased plasma levels of inflam-
matory markers, and increased insulin sensitivity [77]. It
is of note that during the development of periodontitis,
in the attempt to remove causal agents, hyperinflamma-
tion is triggered, attracting numerous neutrophilic gran-
ulocytes, which, through the production of digestive
enzymes during phagocytosis and killing, favor the pro-
duction of ROS and the consequent constant release of
inflammatory mediators with direct bacterial action
damage on periodontal tissue. In addition, it seems that
in people suffering from periodontitis, pathogen bac-
teria, endotoxins, and inflammatory mediators cause
leucocytosis and increased lipidic metabolism, with an
increase of cholesterol and hepatic triglycerides favoring
the risk of CVD [78,79]. Furthermore, a systemic increase
of oxidative stress caused by periodontal disease seems to
promote LDL oxidation [80]. LDLs are cholesterol car-
riers with proinflammatory and pro-atherogenic activity.
Periodontal treatment by scaling and root planning, and
dental care instruction seem to reduce the circulating
oxLDL level and, consequentially, the risk of the onset of
CVD [80]. In addition, leptin seems to be involved in
bone metabolism [74]. In recent murine studies, animals
missing the leptin-codifying gene developed pronounced
obesity. At the same time, mice with an adulterated leptinreceptor presented overweight and T2D [66]. Moreover,
children lacking leptin showed severe obesity, but when
exogenous leptin was given, obesity decreased consider-
ably. In periodontal individuals, serum leptin seems
increased [81,82]. On the contrary, leptin in gingival fluid
shows decreased levels, especially in the presence of
aggressive and advanced periodontitis, advising of a pro-
tective leptin role, although this topic is still disputed [84].
There are no relevant data about the rate of adipo-
nectin in gingival sulcular fluid, but in vitro it has been
shown to be able to inhibit osteoclast activity induced by
LPS. Thus, it seems to have anti-inflammatory and pro-
tective action against the progression of periodontitis
and a predictive role for T2D [74].
In synthesis a recent systematic review confirmed a
positive association between obesity and periodontal
diseases across multiple studies and populations from
around the world, but this relationship needs more
investigation [84]. The relationship appears clarified
when the treatment of obesity is also analyzed. Accord-
ing to a recent study by Lakkis et al. [85] some parodon-
topathic obese patients who underwent bariatric surgery
showed weight loss and fat-mass loss after surgery, and
an improvement in inflammatory conditions with the
reduction of circulating markers and hyperglycemia. In
addition, it seems that patients who undergo bariatric
surgery show an improved response to non-surgical
periodontal therapy compared with obese parodonto-
pathic patients not treated with bariatric surgery. These
data contrast with those reported by a study conducted
by Zouza et al. [86], who showed that non-surgical peri-
odontal treatment allows a reduction of all clinical para-
meters of periodontal inflammation, both in obese
patients and in normal-weight subjects, arguing that
obesity does not negatively affect the success of peri-
odontal therapy. Some studies also try to magnify this
relationship. A recent meta-analysis indicated statisti-
cally significant associations between periodontitis and
body mass index: the category of obese subjects showed
an odds ratio (OR) of 1.81 the category of overweight
subjects showed an OR of 1.27, and obese and over-
weight combined showed an OR of 2.13. Although there
is insufficient evidence to provide guidelines to clinicians
on the clinical management of periodontitis in over-
weight and obese individuals [87], these studies evidence
a clear relationship.
Bariatric surgical procedures, including the laparo-
scopic adjustable gastric band (LAGB), are currently the
only effective treatments for morbid obesity. The LAGB
exerts its effects on satiety, reducing food intake and
body weight by the modulation of both neural and hor-
monal responses, with the latter involving an elevation
of meal-related levels of glucagon-like peptide-1 (GLP-1)
and peptide YY (PYY) [88]. The brain, mainly the
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the balance between food intake and energy expend-
iture by receiving peripheral signals from adipose tissue
(adipose signals) and responding to them. Several neuro-
peptides are involved in this process, such as neuropep-
tide Y (NPY), which increases food consumption and
decreases energy expenditure. NPY, acting through spe-
cific receptors, plays an important role in several physio-
logical functions, including cardiovascular homeostasis
and regulation of sympathetic nervous system activity. It
mediates stress-induced obesity in adult male mice by
activating its Y2 receptor (Y2R) in visceral adipose tissue.
In fact, the expression of NPY is correlated with body
weight changes, rather than with the presence of type 2
diabetes [89].
Chemerin is a recently identified adipokine that is
highly expressed in liver and adipose tissue and is asso-
ciated with adiposity, insulin resistance, MetS risk fac-
tors, and degree of nonalcoholic fatty liver. Importantly,
chemerin is thought to regulate adipogenesis and meta-
bolic homeostasis in murine and human adipocytes.
Additionally, it modulates the innate immune system
through its binding to the orphan G-protein coupled
receptor chemokine-like receptor 1. It also modulates
chemotaxis of immature dendritic cells and macro-
phages. Recent studies have associated chemerin with
several inflammatory markers in obesity and T2D. Thus,
chemerin is considered as a candidate in linking inflam-
mation to obesity-related diseases [90].
Weight gain and the appearance of insulin resistance
go hand in hand and are thought to be caused by an
abnormal adipokine release by visceral fat. Adipocytes
release retinol binding protein 4 (RBP4) and visfatin,
and their plasma levels are elevated in individuals with
abdominal obesity. The observation that RBP4 induces
insulin resistance by interfering with insulin receptor
substrate 1 adds to the list of plasma abnormalities that
link obesity with the development of T2D. At levels
found in vivo these adipokines interfere with insulin
receptor substrate 1 regulation (short contact) and induce
its degradation (prolonged contact) [91]. Another treat-
ment for obesity consists of behavioral weight manage-
ment interventions, which consistently produce 8% to 10%
reductions in body weight, although most subjects regain
weight after treatment ends. One strategy for extending
the effects of behavioral interventions has been the
provision of extended care, which is a viable and effica-
cious solution to addressing the long-term maintenance of
lost weight. Given the chronic disease nature of obesity,
extended care may be necessary for long-term health
benefits [92].
About the modulation of both neural and hormonal
responses, periodontitis has also been associated with
preterm birth. For many years, the incidence of pretermbirth has not decreased in developed countries despite
the promotion of public health programs. Many risk
factors have been identified, including ethnicity, age,
tobacco, and infection. However, the causes of almost
50% of preterm births remain unknown. As periodontal
diseases are highly prevalent and negatively influence
general health, worsening the incidence of CVD and dia-
betes, they have also been suspected to increase the rate of
preterm birth. However, data on this topic remain contra-
dictory. Physicians/obstetricians can identify women at
risk of preterm birth and refer these patients to dentists
for periodontal examination and treatment to limit
adverse pregnancy outcomes [93].
Hypertension and periodontitis
Hypertensives suffering from MetS show increased oxi-
dative stress and compromised antioxidant activity in
plasma and cells [94,95]. In addition, obesity and over-
weight are strictly related to hypertension. In fact,
weight loss determines a diminished blood pressure
independent from sodic diet [95]. Moreover, hypergly-
cemia and hypertension are strictly related. Hyperglycemia
provokes an increased stimulation of a sympathetic
nervous system that causes vasoconstriction and increased
sodium reabsorption with consequent water attraction
and insurgence of hypertension, which damages the endo-
thelium integrity of vessels [96].
Augmented endothelial permeability allows the pas-
sage of lipoproteins and platelet-derived growth factors
(PDGF), which give rise to the proliferation of muscular
smooth cells in the intima, which occludes vessel lumen
and causes embolia, hypoxia, and consequent cellular
death [97].
It also seems that periodontitis can influence some
types of hypertension [98]. Several studies have taken
into consideration the relationship between hypertension
and periodontitis, although an association between peri-
odontal disease measures and incident hypertension in
cohort studies has not yet been evidenced. In a sample
of 31,543 participants of the Health Professionals’
Follow-Up Study, based on a prospective cohort of
40- to 75-year-old men at baseline, with no prior hyper-
tension history and complete baseline information on
oral health, an incidence of 10,828 cases of hypertension
over 20 years of follow-up was identified, with no sig-
nificant association between incident hypertension and
periodontal disease [99].
In a study population of 182 adults, a multivariate ana-
lysis showed no association between severe periodontitis
and hypertension history (OR= 0.99; 95% CI: 0.40-2.48).
Severe periodontitis was associated with high blood
pressure, with an OR of 2.93 (95% CI: 1.25-6.84) after
adjusting for age, gender, smoking, and binge drinking.
This association was stronger when restricted to those
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tions (OR= 4.20; 95% CI: 1.28-13.80), suggesting that
periodontitis may contribute to poor blood pressure
control among older adults [100].
Although statistical evidence is lacking, a clinical rela-
tion between high blood pressure and aggressive peri-
odontitis has been deduced, as patients with poor oral
hygiene have higher blood pressure problems than do
healthy subjects with good oral hygiene condition [99].
Regarding the biological mechanism of this relationship,
a recent study evaluated endothelial function in patients
with periodontitis. Circulating levels of CRP and IL-6
were significantly higher in the periodontitis subjects
with hypertension, than in the control group. Peri-
odontal therapy seems to reduce serum concentrations
of CRP and IL-6 [101].
Metabolic syndrome and periodontitis
As already mentioned, MetS is a syndrome characterized
by several signs that together seriously compromise the
health of an individual. It is clear that the common
denominator of the member pathologies of MetS is oxi-
dative stress and the consequent hyperinflammation that
primes chain interactions and leads to grave systemic
complications, such as CVD, or local complications,
such as periodontitis.
MetS allows a pro-oxidative state in periodontal tissue,
altering antioxidant defense mechanisms. This adversely
affects tissular response against bacterial plaque attack.
On the contrary, periodontitis, being a great source of
oxidative markers, promotes the onset of insulin resist-
ance and MetS in a vicious circle [102]. Chronic inflam-
mation during old age periodontitis causes increased
neutrophil defense activity, which involves increased
oxidative activity, resulting in peroxidation and oxida-
tive stress. In fact, both MetS and periodontitis show
increased serum rates of oxidative stress markers
[103,104].
Regarding the oxidative stress markers found in peri-
odontitis, individuals with periodontal disease exhibit a
significant increase in the activities of oxidative stress
markers. The increase in glutathione peroxidase may
represent possible antioxidant compensation in detoxifi-
cation reactions of organic peroxides produced during
oxidative stress in gingival tissue. Since glutathione
S-transferase (GST) has a direct role in the neutralization
of hydroperoxides derived from the lipoperoxidation pro-
cesses, increases in GST activities are probably related to
the oxidative stress caused by the periodontal inflamma-
tory process. GST comprises a group of enzymes that are
also able to detoxify a variety of compounds, including
xenobiotics derived from pathogenic microorganisms.
Hence, increases in GST activities are excellent indicators
of endogenous detoxification from exogenous sources.Myeloperoxidase activity in gingival tissue has shown a
significant increase in patients with periodontal disease
when compared with controls: this seems indicative of a
chronic inflammatory process also reflected at a systemic
level. A significant increase in oxidized glutathione
(GSSG) concentrations has been detected in periodon-
titis patients, which is a clear biomarker of oxidative
stress detected in inflammatory processes linked to peri-
odontitis. Consistent with the results for GSSG, tissue
lipoperoxidation, measured as thiobarbituric acid react-
ive substances, seems to increase in the gingival tissue of
periodontitis [105]. Periodontal diseases seem related to
pathologies and conditions characterized by high oxida-
tive stress and by the presence of AGE, such as diabetes
and physiologic aging. AGEs are able to favor chemotaxis
and the production of proinflammatory mediators, to
inhibit fibroblasts and osteoblasts, and to accelerate peri-
odontal damage directly or binding their receptors RAGE
[106]. Periodontitis is strictly correlated to hypergly-
cemia; in fact, it is also considered the sixth complication
of diabetes mellitus [61]. Predialysis and hemodialysis in
chronic kidney diseases are also associated with a higher
prevalence of severe periodontitis compared with healthy
individuals.
Chronic kidney failure is a clinical syndrome due to
the slow, progressive, and irreversible loss of the glom-
erular filtration rate, and may be associated with several
oral manifestations, such as xerostomia, uremic stoma-
titis, and periodontitis, diagnosed as clinical attachment
loss.
Recent studies have shown an association between
high levels of CRP and IL-6 and periodontitis, an associ-
ation that decreases after periodontal treatment. Due to
this association with the systemic inflammatory response,
chronic periodontitis has recently been included as a
nontraditional risk factor for chronic kidney failure [107].
In synthesis, metabolic alterations related to MetS
component diseases cause an augmented response to
bacterial plaque, which favors periodontitis insurgence.
It has been pointed in many studies out how periodon-
tal treatment can reduce inflammatory mediators related
to endothelial and cardio-circulatory dysfunctions [108].
A very recent work reported a real relationship between
periodontitis and MetS, especially in women, while
abdominal obesity was the largest contributory factor in
both genders [109]. On the contrary, another new work
about MetS and periodontal diseases and caries did not
find a strong association between MetS and periodontal
infections [110].Odontologic management of metabolic patients
Dentists play a key role in the precocious diagnosis of
MetS and its local complications such as periodontitis.
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The capability of an aliment to raise the level of insulin
in the blood, compared with a reference food such as
glucose or with bread, is known as the glycemic index
(GI) [111,112]. It seems that the greater the consump-
tion of foods with higher GI, the wider will be the risk of
developing insulin resistance, endothelial dysfunction,
and CVD. In fact, taking foods with high GI results in
the quick increase of glycemia and, consequently, in
insulinemia in the attempt to restore glycemia; the secre-
tion of insulin continues in spite of reestablished euglyce-
mia, so as to conduce to a hypoglycemic state [113].
Hypoglycemia causes the secretion of counter-regulatory
hormones, such as corticosteroids, glucagon, and epineph-
rine, with the consequent reduction of lipolysis, glycogen-
olysis, fatty-acid release, and vasoconstriction that can
bring hypertension [114]. Repeating this process may lead
to β-cell damage and T2D. A poor diet of foods with high
GI is basilar to reduce at least the risk factor. Several stud-
ies have demonstrated the relationship between the intake
of foods with high GI and MetS [115]. It is ideal to con-
sume nutrient-rich, high-fiber food such as fruits and
vegetables to maintain good health [116].
Good oral health
Maintaining good oral health is fundamental for indivi-
duals who suffer from MetS and have a tendency to
develop CVD. Progressive loss of teeth produces a vari-
ation of diet, with an increased intake of foods with great
caloric rate, saturated fats, trans fatty acids, and choles-
terol, and less intake of fruits and vegetables rich in vita-
mins and fibers, folate, and potassium [117]. The use of
partial or total removable prosthesis does not seem to
cover the masticatory efficacy of natural teeth [118], but
fixed dental prosthetic devices and prosthetic overim-
plants seem to improve dietary practices [119]. Drugs
used in patients suffering from MetS may give rise to oral
collateral effects and could interact with drugs prescribed
in dentistry [120].
Sibutramine, used in weight control, may cause hyper-
tension and tachycardia, and if associated with opioids,
may provoke serotonin syndrome with confusion, palpi-
tations, and loss of consciousness; the concomitant use
of erythromycin and clarithromycin could lead to tox-
icity. Ace inhibitors, if prescribed in association with
nonsteroidal anti-inflammatory agents, may be inhibited
in their activity. Statin medications in association with
erythromycin and clarithromycin could lead to renal fail-
ure [97]. As diabetes is a member of MetS, dentists may
evaluate glycemic value before starting dental thera-
peutic measures [121].
The oral complications of diabetes are candidiasis,
xerostomia, burning mouth syndrome, gingivitis, oral
acute infections, and, clearly, periodontal diseases – alldiseases treated with dentistry [122]. Therefore, the role
of dentists in the diagnosis, therapy, and management of
metabolic patients is fundamental [123], and an improve-
ment of collaboration among dentists, cardiologists,
endocrinologists, and dietists is needed to promote the
multidisciplinary therapeutic approach to this syndrome.Conclusions
In this review, we tried to explain how various patholo-
gies associated with MetS can be related to and favor
the onset of CVD and, especially, periodontitis. Oxida-
tive stress seems to be the chief suspect in ethiopatho-
genesis of periodontal disease; for this, the use of drugs
with antioxidative activity or anti-AGE is the subject of
research. Chemical agents such as pyridoxamine, metfor-
min, and nefedipine, with their antioxidative ability, could
be used. Other anti-AGE drugs are modified tetracyclines,
such as doxycycline, which have anti-inflammatory and
antioxidative effects. However, this argument needs more
clarity, and the search for answers goes encouraged. As we
await more results, we can increase prevention in at-risk
individuals by advising lifestyle changes and prescribing a
balanced diet to control body weight, hyperlipidemia, and
hypertension; advising a stop to smoking and the mainten-
ance good oral hygiene in periodontal therapy; and finally,
establishing pharmacological and eating control of diabetes.
The role of dentists in the diagnosis, therapy, and
management of metabolic patients is fundamental, but
an improvement of collaboration among dentists, cardi-
ologists, endocrinologists, dietists, etc., is needed.
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